AKRO
Price
$44.71
Change
+$0.68 (+1.54%)
Updated
Sep 5, 04:59 PM (EDT)
Capitalization
3.52B
68 days until earnings call
MDGL
Price
$432.94
Change
+$1.72 (+0.40%)
Updated
Sep 5, 04:59 PM (EDT)
Capitalization
9.61B
55 days until earnings call
Interact to see
Advertisement

AKRO vs MDGL

Header iconAKRO vs MDGL Comparison
Open Charts AKRO vs MDGLBanner chart's image
Akero Therapeutics
Price$44.71
Change+$0.68 (+1.54%)
Volume$23.52K
Capitalization3.52B
Madrigal Pharmaceuticals
Price$432.94
Change+$1.72 (+0.40%)
Volume$4.68K
Capitalization9.61B
AKRO vs MDGL Comparison Chart in %
Loading...
AKRO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MDGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AKRO vs. MDGL commentary
Sep 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AKRO is a StrongBuy and MDGL is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 06, 2025
Stock price -- (AKRO: $44.03 vs. MDGL: $431.21)
Brand notoriety: AKRO and MDGL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AKRO: 141% vs. MDGL: 65%
Market capitalization -- AKRO: $3.52B vs. MDGL: $9.61B
AKRO [@Biotechnology] is valued at $3.52B. MDGL’s [@Biotechnology] market capitalization is $9.61B. The market cap for tickers in the [@Biotechnology] industry ranges from $101.77B to $0. The average market capitalization across the [@Biotechnology] industry is $1.87B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AKRO’s FA Score shows that 0 FA rating(s) are green whileMDGL’s FA Score has 1 green FA rating(s).

  • AKRO’s FA Score: 0 green, 5 red.
  • MDGL’s FA Score: 1 green, 4 red.
According to our system of comparison, MDGL is a better buy in the long-term than AKRO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AKRO’s TA Score shows that 4 TA indicator(s) are bullish while MDGL’s TA Score has 6 bullish TA indicator(s).

  • AKRO’s TA Score: 4 bullish, 5 bearish.
  • MDGL’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, MDGL is a better buy in the short-term than AKRO.

Price Growth

AKRO (@Biotechnology) experienced а -6.20% price change this week, while MDGL (@Biotechnology) price change was -1.36% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.44%. For the same industry, the average monthly price growth was +9.94%, and the average quarterly price growth was +31.78%.

Reported Earning Dates

AKRO is expected to report earnings on Nov 12, 2025.

MDGL is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Biotechnology (+2.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MDGL($9.61B) has a higher market cap than AKRO($3.52B). AKRO YTD gains are higher at: 58.267 vs. MDGL (39.745). MDGL (-266.74M) and AKRO (-279.17M) have comparable annual earnings (EBITDA) . MDGL has more cash in the bank: 797M vs. AKRO (742M). AKRO has less debt than MDGL: AKRO (37.2M) vs MDGL (124M). MDGL has higher revenues than AKRO: MDGL (516M) vs AKRO (0).
AKROMDGLAKRO / MDGL
Capitalization3.52B9.61B37%
EBITDA-279.17M-266.74M105%
Gain YTD58.26739.745147%
P/E RatioN/AN/A-
Revenue0516M-
Total Cash742M797M93%
Total Debt37.2M124M30%
FUNDAMENTALS RATINGS
AKRO vs MDGL: Fundamental Ratings
AKRO
MDGL
OUTLOOK RATING
1..100
7122
VALUATION
overvalued / fair valued / undervalued
1..100
34
Fair valued
67
Overvalued
PROFIT vs RISK RATING
1..100
8426
SMR RATING
1..100
9797
PRICE GROWTH RATING
1..100
5337
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AKRO's Valuation (34) in the null industry is somewhat better than the same rating for MDGL (67) in the Pharmaceuticals Other industry. This means that AKRO’s stock grew somewhat faster than MDGL’s over the last 12 months.

MDGL's Profit vs Risk Rating (26) in the Pharmaceuticals Other industry is somewhat better than the same rating for AKRO (84) in the null industry. This means that MDGL’s stock grew somewhat faster than AKRO’s over the last 12 months.

MDGL's SMR Rating (97) in the Pharmaceuticals Other industry is in the same range as AKRO (97) in the null industry. This means that MDGL’s stock grew similarly to AKRO’s over the last 12 months.

MDGL's Price Growth Rating (37) in the Pharmaceuticals Other industry is in the same range as AKRO (53) in the null industry. This means that MDGL’s stock grew similarly to AKRO’s over the last 12 months.

MDGL's P/E Growth Rating (100) in the Pharmaceuticals Other industry is in the same range as AKRO (100) in the null industry. This means that MDGL’s stock grew similarly to AKRO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AKROMDGL
RSI
ODDS (%)
Bullish Trend 2 days ago
88%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
77%
MACD
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
85%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 2 days ago
77%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 2 days ago
76%
Advances
ODDS (%)
Bullish Trend 10 days ago
83%
Bullish Trend 8 days ago
78%
Declines
ODDS (%)
Bearish Trend 4 days ago
84%
Bearish Trend 2 days ago
80%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
84%
N/A
Aroon
ODDS (%)
Bearish Trend 2 days ago
79%
Bullish Trend 2 days ago
80%
View a ticker or compare two or three
Interact to see
Advertisement
AKRO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MDGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
FPXE31.580.27
+0.87%
First Trust IPOX Europe Equity Opps ETF
GSEW84.100.61
+0.73%
Goldman Sachs Equal Wght US Lg Cp Eq ETF
JPI20.420.09
+0.42%
Nuveen Preferred Securities & Income Opportunities Fund
PSMO29.830.09
+0.30%
Pacer Swan SOS Moderate (October) ETF
LDRI25.68N/A
N/A
iShares iBonds 1-5 Year TIPS Ladder ETF

AKRO and

Correlation & Price change

A.I.dvisor indicates that over the last year, AKRO has been loosely correlated with ETNB. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if AKRO jumps, then ETNB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AKRO
1D Price
Change %
AKRO100%
-3.49%
ETNB - AKRO
60%
Loosely correlated
-6.82%
SLS - AKRO
43%
Loosely correlated
N/A
VTYX - AKRO
38%
Loosely correlated
+0.78%
MDGL - AKRO
37%
Loosely correlated
-0.93%
IDYA - AKRO
36%
Loosely correlated
+0.27%
More

MDGL and

Correlation & Price change

A.I.dvisor indicates that over the last year, MDGL has been loosely correlated with NAGE. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if MDGL jumps, then NAGE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MDGL
1D Price
Change %
MDGL100%
-0.93%
NAGE - MDGL
45%
Loosely correlated
-3.62%
RVMD - MDGL
39%
Loosely correlated
-2.06%
AKRO - MDGL
37%
Loosely correlated
-3.49%
IRON - MDGL
36%
Loosely correlated
-2.27%
ADMA - MDGL
35%
Loosely correlated
+0.03%
More